|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 799 9th St NW |
Address2 | Suite 210 |
City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Irving |
State | TX |
Zip Code | 75062 |
Country | USA |
|
5. Senate ID# 40021-00012
|
||||||||
|
6. House ID# 313240000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Shoshana Krilow |
Date | 4/19/2019 2:31:03 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Disproportionate Share Hospital (DSH) Payments - Urged Congress to continue delay of implementation of Medicaid DSH payment cuts.
ACE Kids Act (H.R. 1226, S.317) - Urged passage of ACE Kids Act to promote greater care coordination and expand Medicaid treatment options for medically complex pediatric patients.
Site-neutral Payments - Opposed efforts to reduce payment rates for hospital outpatient departments. Advocated for Congress to reverse site-neutral payments cuts implemented by the Centers for Medicare and Medicaid Services in the 2019 Outpatient Prospective Payment System final rule.
Resident Physician Shortage Reduction Act (S. 348) - Supported passage of the Resident Physician Shortage Reduction Act to support an increase in the number of Medicare-supported graduate medical education residents.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Chelsea |
Arnone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Hospital Group Purchasing - Advocated in support of hospital group purchasing organizations and maintaining the GPO safe harbor.
Overall Hospital Quality Star Ratings System - Urged changes to the methodology of the Overall Hospital Quality Star Ratings System.
340B Drug Pricing Program - Supported maintaining adequate reimbursement for hospitals purchasing prescription drugs through the 340B Drug Pricing Program. Advocated for maintaining the current structure of the program and supported retaining the current prime vendor.
Prescription Drug Pricing - Urged passage of legislation that would promote competition among prescription drug manufacturers. Supported passage of the CREATES Act (H.R. 965; S. 340). Supported passage of the FAST Generics Act (H.R. 985). Supported passage of Biologic Patent Transparency Act (S.659). Monitored ongoing Congressional discussions related modifying pharmacy benefit manager rebates and other legislation related to patents, pay-for-delay settlements and improvements to FDA resources regarding biosimilar medications.
Medical Device and Hospital Cybersecurity - Monitored ongoing discussion around enhancing cybersecurity protections for medical devices and hospital networks. Supported additional resources to bolster efforts as well as regulatory flexibility that recognizes the complexity of preventing and responding to cyberattacks.
Disaster Preparedness - Conducted education and outreach to describe hospital efforts and resources necessary to prepare for natural disasters and mass-casualty events.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Chelsea |
Arnone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Not-for-Profit Hospital Tax Exemption - monitored discussions in Congress regarding possible changes to hospital tax-exemption and community benefit requirements to require minimum charity care levels to maintain tax-exempt status.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Shoshana |
Krilow |
|
|
|
Steven |
Rixen |
|
|
|
Chelsea |
Arnone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |